Excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1) is a critical gene in the Nucleotide excision repair pathway. A growing list of reports links cisplatin, carboplatin, and oxaliplatin based chemotherapy resistance to ERCC1 expression levels in several tumors. ERCC1 has been shown to be an important marker to predict responsiveness to cisplatin-based chemotherapy. Low ERCC1 gene expression correlates with prolonged survival after cisplatin-based chemotherapy. The ERCC1 (19q13) FISH probe has been optimized to detect copy numbers of the ERCC1 gene region at 19q13. The ZNF443 (19p13) probe is included to facilitate chromosome identification.
References: Olaussen et al, 2006, N. Engl. J. Med. 335; 983-991. Ceppi et al, 2006, Ann. Oncol. 17; 1818-1825.
